---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical presentation - signs and symptoms"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: Clinical presentation - signs and symptoms. Topics: Nocturnal symptoms: snoring, witnessed apneas, gasping or choking, nocturia, and morning headaches; Daytime symptoms: unrefreshing sleep, fatigue, and sleepiness; Daytime symptoms: sleepiness across respiratory disturbance index levels in the Sleep Heart Health Study; Neurocognitive and psychosocial symptoms: vigilance, concentration, cognition, and quality of life; 6 further topics. 10 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description/clinical-presentation-signs-and-symptoms"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical presentation - signs and symptoms

<a id="heading-2.2.1.6"></a>

## 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

### Nocturnal symptoms: snoring, witnessed apneas, gasping or choking, nocturia, and morning headaches

> “A comprehensive sleep history in a patient suspected of OSA should include an evaluation for snoring, witnessed apneas, gasping/choking episodes, excessive sleepiness not explained by other factors, including assessment of sleepiness severity by the Epworth Sleepiness Scale,”
> “total sleep amount, nocturia, morning headaches, sleep fragmentation/sleep maintenance insomnia, and decreased concentration and memory (Consensus).”

Source: [Epstein et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2699173/)

<a id="topic-2.2.1.6-2"></a>

### Daytime symptoms: unrefreshing sleep, fatigue, and sleepiness

> “Individuals with OSA often feel unrested, fatigued, and sleepy during the daytime.”

Source: [Kapur et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5337595/)

<a id="topic-2.2.1.6-3"></a>

### Daytime symptoms: sleepiness across respiratory disturbance index levels in the Sleep Heart Health Study

> “Sleep-disordered breathing was quantified by the respiratory disturbance index (RDI), defined as the number of apneas plus hypopneas per hour of sleep, measured during in-home polysomnography.”
> “When RDI was categorized into four groups (< 5, 5 to < 15, 15 to < 30, >/= 30), a significantly progressive increase in mean ESS score was seen across all four levels of SDB, from 7.2 (4.3) in subjects with RDI < 5 to 9.3 (4.9) in subjects with RDI >/= 30 (p < 0.001).”
> “The percentage of subjects with excessive sleepiness, defined as an ESS score >/= 11, increased from 21% in subjects with RDI < 5 to 35% in those with RDI >/= 30 (p < 0. 001).”

Source: [Gottlieb et al. (1999)](https://pubmed.ncbi.nlm.nih.gov/9927364/)

<a id="topic-2.2.1.6-4"></a>

### Neurocognitive and psychosocial symptoms: vigilance, concentration, cognition, and quality of life

> “They may suffer from impairments in vigilance, concentration, cognitive function, social interactions and quality of life (QOL). These declines in daytime function can translate into higher rates of job-related and motor vehicle accidents.”

Source: [Kapur et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5337595/)

<a id="topic-2.2.1.6-5"></a>

### Insomnia symptoms: comorbid insomnia and obstructive sleep apnea

> “Co-morbid insomnia has been found to be a frequent problem in patients with OSA.”

Source: [Kapur et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5337595/)

> “The largest prospective observational study of active-duty service members referred to a sleep center diagnosed insomnia in 32.7% of patients, OSA in 30.4%, and comorbid insomnia and obstructive sleep apnea (COMISA) in 36.9%.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.1.6-6"></a>

### Physical signs: obesity, neck circumference, and upper airway anatomy

> “Particular attention should be paid to the presence of obesity, signs of upper airway narrowing, or the presence of other disorders that can contribute to the development of OSA or to the consequences of OSA.”
> “body mass index (BMI) ≥ 30 kg/m2, a Modified Mallampati score of 3 or 4”
> “the presence of retrognathia, lateral peritonsillar narrowing, macroglossia, tonsillar hypertrophy, elongated/enlarged uvula, high arched/narrow hard palate, nasal abnormalities (polyps, deviation, valve abnormalities, turbinate hypertrophy) and/or overjet (Consensus).”

Source: [Epstein et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2699173/)

<a id="topic-2.2.1.6-7"></a>

### Cardiometabolic presentation: conditions that place patients at high risk of OSA

| High-risk group | Quoted entry |
| --- | --- |
| Obesity | “Obesity (BMI > 35)” |
| Heart failure | “Congestive heart failure” |
| Arrhythmia | “Atrial fibrillation” |
| Hypertension | “Treatment refractory hypertension” |
| Diabetes | “Type 2 diabetes” |
| Arrhythmia | “Nocturnal dysrhythmias” |
| Cerebrovascular disease | “Stroke” |
| Pulmonary vascular disease | “Pulmonary hypertension” |
| Occupational | “High-risk driving populations” |
| Surgical | “Preoperative for bariatric surgery” |

Source: [Epstein et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2699173/)

<a id="topic-2.2.1.6-8"></a>

### Symptom subtypes: disturbed sleep, minimally symptomatic, excessively sleepy, and moderately sleepy in the Sleep Heart Health Study

> “Data from 1,207 patients with OSA (apnea–hypopnea index ≥ 15 events/h) were used to evaluate the existence of symptom subtypes using latent class analysis.”
> “Four symptom subtypes were identified (disturbed sleep [12.2%], minimally symptomatic [32.6%], excessively sleepy [16.7%], and moderately sleepy [38.5%]), similar to prior studies.”

Source: [Mazzotti et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6701040/)

<a id="topic-2.2.1.6-9"></a>

### Minimally symptomatic presentation: undiagnosed and minimally sleepy populations

> “While most of these cases are undiagnosed, it is likely that most are asymptomatic or minimally symptomatic, and it remains uncertain whether these individuals have a disorder that requires therapeutic intervention”

Source: [Malhotra et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8271129/)

> “Most of the participants were men who had moderate-to-severe obstructive sleep apnea and minimal sleepiness.”

Source: [McEvoy et al. (2016)](https://www.nejm.org/doi/full/10.1056/NEJMoa1606599)

<a id="topic-2.2.1.6-10"></a>

### Sex differences in symptoms: matched men and women across AHI strata

> “Study participants were classified as having no SDB (apnea-hypopnea index [AHI] <5 events/h), mild SDB (5.0-14.9 events/h), or moderate-to-severe SDB (≥15 events/h). Within each stratum, men and women were matched 1:1 on age, race, body mass index, and AHI.”
> “whereas women had more insomnia symptoms and lower physical and mental quality-of-life scores (both p = 0.001)”
> “Comparable levels of SDB severity carry different physiologic and symptomatic consequences in men and women, indicating that assessment should extend beyond AHI alone to include sleep disruption, symptom profile, and functional impact.”

Source: [Hurst et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42600422/)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
